home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AlloVir, Inc. - Common Stock (NQ:ALVR)

9.810 UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AlloVir, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer

May 16, 2023

From AlloVir

Via Business Wire

AlloVir: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

AlloVir Reports First Quarter 2023 Financial Results

May 04, 2023

From AlloVir

Via Business Wire

AlloVir to Present at the BofA Securities 2023 Health Care Conference

May 01, 2023

From AlloVir, Inc.

Via Business Wire

Recap: AlloVir Q2 Earnings ↗

August 04, 2022

AlloVir (NASDAQ:ALVR) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

AlloVir's Posoleucel Achieves Non-Relapse Mortality Of 0% In Transplant Patients For Viral Infections ↗

April 26, 2023

AlloVir Inc (NASDAQ: ALVR) announced the presentation of long-term, follow-up data from the Phase 2 study of posoleucel to prevent infections from six viruses in allogeneic hematopoietic cell...

Via Benzinga

AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023

April 26, 2023

From AlloVir, Inc.

Via Business Wire

Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday ↗

April 13, 2023

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 09, 2023

Via Benzinga

AlloVir Appoints Derek Adams, Ph.D., to Board of Directors

February 23, 2023

From AlloVir

Via Business Wire

AlloVir Announces Final Results From Posoleucel Study In Kidney Transplant Recipients With BK Viremia, Shares Fall ↗

February 15, 2023

Via Benzinga

AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook

February 15, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

February 15, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir to Participate in the SVB Securities Global Biopharma Conference

February 01, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

January 09, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition

December 10, 2022

From AlloVir

Via Business Wire

AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 15, 2022

From AlloVir

Via Business Wire

AlloVir: Q3 Earnings Insights ↗

November 03, 2022

AlloVir (NASDAQ:ALVR) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings AlloVir beat estimated earnings by...

Via Benzinga

Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting

November 03, 2022

From AlloVir, Inc.

Via Business Wire

AlloVir Reports Third Quarter 2022 Financial Results

November 03, 2022

From AlloVir, Inc.

Via Business Wire

Moderna, Zscaler And This Biotechnology Stock Insiders Are Selling ↗

October 03, 2022

US crude oil futures traded higher this morning on Monday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Why Super Micro Computer Shares Jumped Over 10%; Here Are 73 Biggest Movers From Yesterday ↗

October 21, 2022

Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares climbed 107.3% to close at $0.4138 on Thursday after the company announced its NextFintech division received commitment for a $15 million...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 31, 2022

Via Benzinga

AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

August 31, 2022

From AlloVir, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 11, 2022

Via Benzinga

Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday ↗

August 12, 2022

Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.

Via Benzinga

Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session ↗

August 11, 2022

Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering.

Via Benzinga

Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday ↗

August 10, 2022

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.

Via Benzinga

Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session ↗

August 09, 2022

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD....

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com